[1] 李华芳,马崔,王刚,等.奎硫平与锂盐治疗双相障碍急性躁狂的随机双盲对照多中心研究[J].中华精神科杂志,2008,41(2):85-88. [2] 任志斌,童振华,金卫东,等.齐拉西酮与利培酮治疗精神分裂症对照研究的Meta分析[J]. 精神医学杂志,2008, 21(5) :350-352. [3] 王晓蓉,任志斌,金卫东.齐拉西酮与奥氮平治疗精神分裂症对照研究引起体重和血糖增加的Meta分析[J].中国全科医学,2011,14(6):596-597. [4] Bowden CL, Vieta E, Ice KS, et al.Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial[J].J Clin Psychiatry, 2010 ,71(2):130-137. [5] Dubovsky SL, Dubovsky AN.Ziprasidone for maintenance treatment of bipolar I disorder in adults[J]. Expert Opin Pharmacother, 2011,12(5):817-824. [6] 马永春,金卫东.齐拉西酮治疗双相心境障碍[J].国际精神病学杂志,2009,36(3):181-183. [7] Keck PE Jr, Versiani M, Potkin S, et al.Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial[J].Am J Psychiatry,2003 ,160(4):741-748. [8] Potkin SG, Keck PE Jr, Segal S, et al.Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial[J].J Clin Psychopharmacol,2005, 25(4): 301-310. [9] Kim E, Maclean R, Ammerman D, et al.Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis[J]. Clin Ther, 2009,31(4):836-848. [10] Kim E, You M, Pikalov A, et al.One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis[J].BMC Psychiatry, 2011,7(11):6. |